AMLX Stock Analysis: Amylyx Pharmaceuticals | NASDAQ
Drug Manufacturers - Specialty & Generic | NASDAQ, USA | Market Cap: 1.976m USD | 12M Return: 107% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 28.1M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 4.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Amylyx Pharmaceuticals is a U.S.-based, clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative diseases and rare endocrine conditions. Its pipeline includes Avexitide, a first-in-class GLP-1 receptor antagonist in Phase 3 trials for post-bariatric hypoglycemia and congenital hyperinsulinism, and AMX0035, an oral fixed-dose combination of sodium phenylbutyrate and taurursodiol being evaluated in Phase 2/3 studies for Wolfram syndrome and progressive supranuclear palsy. Earlier-stage programs include AMX0114 for amyotrophic lateral sclerosis and additional long-acting GLP-1 receptor antagonists targeting rare diseases.
As a clinical-stage company, Amylyx does not yet generate commercial product revenue and is reliant on capital markets and partnerships to fund R&D, a typical model for pre-commercial biotechs. The companys work on GLP-1 receptor antagonists is notable given that the broader GLP-1 therapeutic class is dominated by receptor agonists used for diabetes and obesity, with Amylyxs antagonist approach targeting underserved rare endocrine indications. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company listed on NASDAQ in January 2022.
- Avexitide Phase 3 data readout in post-bariatric hypoglycemia
- Relyvrio discontinuation eliminates near-term commercial revenue
- Cash runway concerns persist amid clinical-stage pipeline development
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.41 > 0.02 and ΔFCF/TA 53.22 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.41 > 3% & CFO -120.4m > Net Income -150.1m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 17.85 > 1.5 & < 3 |
| Outstanding Shares: last quarter (110.6m) vs 12m ago 29.02% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 39.77%; Δ -39.77% > 0%) |
| Interest Coverage Ratio: -78.15 > 6 (EBIT TTM -148.2m / Interest Expense TTM 1.90m) |
| A: 0.92 (Total Current Assets 285.0m - Total Current Liabilities 16.0m) / Total Assets 293.6m |
| B: -2.70 (Retained Earnings -792.7m / Total Assets 293.6m) |
| C: -0.58 (EBIT TTM -148.2m / Avg Total Assets 256.6m) |
| D: 13.36 (Book Value of Equity 273.2m / Total Liabilities 20.4m) |
| Altman-Z'' = 7.36 = AAA |
As of July 14, 2026, the stock is trading at USD 17.41 with a total of 1,468,236 shares traded. Over the past week, the price has changed by -3.12%, over one month by +14.61%, over three months by +5.71% and over the past year by +107.02%.
Current recommended Stop Loss: 14.70 (which is 15.6% or 2.7 ATR below the current price).
Amylyx Pharmaceuticals has received a consensus analysts rating of 4.57. Therefore, it is recommended to buy AMLX.
- StrongBuy: 5
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 24.4 | 40.1% |
P/E Forward = 2.7739
P/S = 0.6625
P/B = 7.233
Revenue TTM = 0.0 USD
EBIT TTM = -148.2m USD
EBITDA TTM = -147.7m USD
Long Term Debt = 4.48m USD (estimated: total debt 5.63m - short term 1.16m)
Short Term Debt = 1.16m USD (from shortTermDebt, last quarter)
Debt = 5.63m USD (from shortLongTermDebtTotal, last quarter) (leases 5.63m already included)
Net Debt = -274.1m USD (calculated: Debt 5.63m - CCE 279.8m)
Enterprise Value = 1.70b USD (1.98b + Debt 5.63m - CCE 279.8m)
Interest Coverage Ratio = -78.15 (Ebit TTM -148.2m / Interest Expense TTM 1.90m)
EV/FCF = -14.12x (Enterprise Value 1.70b / FCF TTM -120.5m)
FCF Yield = -7.08% (FCF TTM -120.5m / Enterprise Value 1.70b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 20.2m) / Revenue TTM)
Tobins Q-Ratio = 5.80 (Enterprise Value 1.70b / Total Assets 293.6m)
Interest Expense / Debt = 33.67% (Interest Expense 1.90m / Debt 5.63m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -117.1m (EBIT -148.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 17.85 (Total Current Assets 285.0m / Total Current Liabilities 16.0m)
Debt / Equity = 0.02 (Debt 5.63m / totalStockholderEquity, last quarter 273.2m)
Debt / EBITDA = 1.86 (negative EBITDA) (Net Debt -274.1m / EBITDA -147.7m)
Debt / FCF = 2.27 (negative FCF - burning cash) (Net Debt -274.1m / FCF TTM -120.5m)
Total Stockholder Equity = 269.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -58.49% (Net Income -150.1m / Total Assets 293.6m)
RoE = -55.69% (Net Income TTM -150.1m / Total Stockholder Equity 269.6m)
RoCE = -54.07% (EBIT -148.2m / Capital Employed (Equity 269.6m + L.T.Debt 4.48m))
RoIC = -41.99% (negative operating profit) (NOPAT -117.1m / Invested Capital 278.8m)
WACC = 9.16% (E(1.98b)/V(1.98b) * Re(9.11%) + D(5.63m)/V(1.98b) * Rd(33.67%) * (1-Tc(0.21)))
Discount Rate = 9.11% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 92.09 | Cagr: 23.16%
[DCF] Fair Price = unknown (Cash Flow -120.5m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.12 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.35 | Chg30d=+0.00% | Revisions=+0% | Analysts=8
EPS next Quarter (2026-09-30): EPS=-0.33 | Chg30d=+0.00% | Revisions=+0% | Analysts=8
EPS current Year (2026-12-31): EPS=-1.38 | Chg30d=+0.00% | Revisions=-10% | GrowthEPS=+9.5% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-1.27 | Chg30d=+0.00% | Revisions=-10% | GrowthEPS=+8.6% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -8% (up=10, down=12)